Howell F. Moffett

This paper designs a transgene that enhances CAR T cell persistence and tumor regression by integrating multiple engineered technologies in solid tumor models.

This paper designs a dynamically regulated IL-2 variant that enhances tumor-specific immune responses while reducing systemic toxicity.

This paper designs proteins to reprogram T cell signaling pathways, improving CAR-T and TCR-T performance in solid tumor models.